Scribe Therapeutics (SCTX) stock
NASDAQ
As of the Nov 13, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- Not available
- Date not confirmed
- P/E
- Not available
- Trailing twelve months
- P/B
- Not available
- Latest reported equity
- P/S
- Not available
- Trailing twelve months
- ROE
- Not available
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
The price date behind the multiples is not confirmed; they may differ from the current price.
- Market cap
- Not available
- Date not confirmed
- P/E
- Not available
- Trailing twelve months
- P/B
- Not available
- Latest reported equity
- P/S
- Not available
- Trailing twelve months
- ROE
- Not available
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
The price date behind the multiples is not confirmed; they may differ from the current price.
Latest earnings
SEC filingsFY2026 Q3
Revenue in the latest quarter: $2M.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
No year-ago figure was found for this quarter.
—
FY24 Q3
—
FY25 Q3
$2M
FY26 Q3
Blank bars mark quarters with no figure found in the filings.
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for FY2026 Q3 are from the 10-Q submitted to SEC EDGAR on Nov 12, 2026.
- Earnings per share has no year-ago figure on record, so no comparison is made.
- Revenue has no year-ago figure on record, so no comparison is made.
- Operating income has no year-ago figure on record, so no comparison is made.
- Net income has no year-ago figure on record, so no comparison is made.
Filed Nov 12, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Aghazadeh BehzadDirector · Jul 28, 2026Open-market purchase7,905 shares · $144KAvg. price $18.253,088,888 shares held after
- GORDON CARL LDirector · Jul 27, 2026Open-market purchase1,000,000 shares · $15.0MAvg. price $151,348,825 shares held after
- ORBIMED ADVISORS LLCDirector · Jul 27, 2026Open-market purchase1,000,000 shares · $15.0MAvg. price $151,348,825 shares held after
- AH Bio Fund II, L.P.10% owner · Jul 27, 2026Open-market purchase333,333 shares · $5.0MAvg. price $152,385,075 shares held after
- ORBIMED ADVISORS LLCDirector · Jul 27, 2026Conversion348,825 shares348,825 shares held after
- AH Bio Fund II, L.P.10% owner · Jul 27, 2026Conversion2,749,392 shares
Show 2 price lots
- 2,051,742 sharesValue not reported
- 697,650 sharesValue not reported
- GORDON CARL LDirector · Jul 27, 2026Conversion348,825 shares348,825 shares held after
- Doudna Jennifer A10% owner · Jul 27, 2026Conversion12,511 shares603,547 shares held after
- Aghazadeh BehzadDirector · Jul 24, 2026Open-market purchase2,383,333 shares · $36.1MAvg. price $15.1534
Show 2 price lots
- 2,333,333 shares × $15$35.0M
- 50,000 shares × $22.31$1.1M
- Lucas SvetlanaChief Business Officer · Jul 23, 2026Open-market purchase3,000 shares · $45KAvg. price $153,000 shares held after
- Parrot DavidChief Financial Officer · Jul 23, 2026Open-market purchase2,666 shares · $40KAvg. price $151,333 shares held after
Show 2 price lots
- 1,333 shares × $15$20K
- 1,333 shares × $15$20K
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
21 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Scribe Therapeutics (SCTX) stock information
NASDAQ
Scribe Therapeutics (SCTX) is listed on NASDAQ. These figures are computed in-house from official filings and are reference information only.
Scribe Therapeutics — frequently asked questions
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.